QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.014753v1 68/6/1699    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gray, M. D. Articles by Hendershot, L. M. Search for Related Content PubMed PubMed Citation Articles by Gray, M. D. Articles by Hendershot, L. M.

Activation of the Unfolded Protein Response Is Necessary and Sufficient for Reducing Topoisomerase II Protein Levels and Decreasing Sensitivity to Topoisomerase-Targeted Drugs

Departments of Molecular Pharmacology (M.D.G., J.L.N.) and Genetics & Tumor Cell Biology (M.M., L.M.H.), St. Jude Children's Research Hospital, Memphis, Tennessee

A wide range of chemotherapeutic agents has been identified that are active against solid tumors. However, resistance remains an important obstacle to the development of curative regimens. Whereas much attention has been paid to acquired drug resistance, a variety of physiological pathways also have been described that reduce the sensitivity of previously untreated tumors to cytotoxic antitumor agents. Treatment of cells with pharmacological agents that alter the environment of the endoplasmic reticulum (ER) and activate the unfolded protein response (UPR) can render cells resistant to topoisomerase II poisons. We describe experiments showing that activation of the mammalian ER stress response is both necessary and sufficient to decrease topoisomerase II protein levels and to render cells resistant to etoposide, a topoisomerase II-targeting drug. This is not caused by the elevated levels of BiP that are a hallmark of this response, because a cell line that has been engineered to overexpress BiP does not show increased resistance to etoposide. The UPR was shown to be required for altered drug sensitivity, because the BiP-overexpressing cell line, which is unable to activate the UPR, did not show decreased topoisomerase II levels or increased resistance to etoposide in response to stress conditions. The transient overexpression of an unfolded protein activated the UPR and led to the concomitant loss of topoisomerase II protein from the cells, demonstrating that UPR activation is sufficient for the changes in topoisomerase II levels that had been observed previously with pharmacological induction of the UPR.

Address correspondence to: Dr. John L. Nitiss, St. Jude Children's Research Hospital, Molecular Pharmacology Department, 332 N. Lauderdale, Memphis, TN 38105. E-mail: john.nitiss{at}stjude.org

This article has been cited by other articles:

				O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]

				J. L. Little, F. B. Wheeler, D. R. Fels, C. Koumenis, and S. J. Kridel Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells Cancer Res., February 1, 2007; 67(3): 1262 - 1269. [Abstract] [Full Text] [PDF]